Metabolic syndrome among HIV infected patients: A comparative cross sectional study in northwestern Nigeria

Diabetes Metab Syndr. 2017 Nov:11 Suppl 1:S523-S529. doi: 10.1016/j.dsx.2017.03.046. Epub 2017 Apr 5.

Abstract

Introduction: The increasing availability of antiretroviral drugs has made HIV-positive patients to live longer, and conditions that are associated with longevity such as metabolic syndrome and other cardiovascular related conditions have become relevant in them. This is less well studied among African populations. Therefore the study aimed at estimating and comparing the prevalence of and associated risk factors for the metabolic syndrome (MS) among African HIV infected patients.

Method: In this comparative cross-sectional study, we analyzed the data of 300 participants matched for age and gender who satisfied the inclusion criteria with half of the subjects on HAART, while the other half was HAART naïve. The MS was diagnosed using ATP-III criteria.

Results: The mean age of the patients was 34.8±9.9years. The majority of the patients were females 64%. The prevalence of MS among HAART-exposed patients was found to be 19.3%, while it was 5.3% among HAART naïve patients (p=0.001). Raised triglyceride and elevated blood pressure were the criteria with the highest occurrence among HAART-exposed, 82.8% for each. Advanced age, longer duration of HIV diagnosis and HAART exposure, increased BMI, weight gain after HAART exposure, exposure to PIs and increased mean CD4 cell count were found to be significantly associated with MS (p<0.05). However, only age (OR 4.3, 95% CI 1.6-11.8, p=0.005) and BMI (OR 4.2, 95% CI 1.5-11.9, p=0.007) were found to be independently associated with the development of MS.

Conclusion: Exposure to HAART particularly protease inhibitor based regimen increases the risk of MS among HIV-infected patients.

Keywords: HAART; HIV; Metabolic syndrome; Northwestern Nigeria.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Age Factors
  • Antiretroviral Therapy, Highly Active / adverse effects
  • Body Mass Index
  • Cross-Sectional Studies
  • Female
  • HIV Infections / complications*
  • Humans
  • Male
  • Metabolic Syndrome / complications
  • Metabolic Syndrome / epidemiology*
  • Middle Aged
  • Nigeria / epidemiology
  • Prevalence
  • Protease Inhibitors / adverse effects
  • Protease Inhibitors / therapeutic use
  • Risk Factors

Substances

  • Protease Inhibitors